Market Overview

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

Share:

AmpliPhi's wholly owned GMP facility now capable of producing material
for over 100,000 doses from each drug substance batch of AB-SA01,
sufficient to support clinical trial requirements

AmpliPhi Biosciences Corporation (NYSE:APHB), a clinical-stage
biotechnology company focused on precisely targeted bacteriophage
therapeutics for patients with serious and life-threatening
antibiotic-resistant bacterial infections, today announced a 10-fold
increase in yield from its manufacturing process, the result of a
continuous and ongoing effort to enhance manufacturing efficiencies for
AB-SA01, the company's clinical stage lead drug product candidate.
AB-SA01 is a targeted bacteriophage therapeutic in clinical development
for the treatment of serious and life-threatening S. aureus
infections, including those that do not respond to antibiotic therapy.

"The improved manufacturing productivity that we have achieved for
AB-SA01 is an important milestone for AmpliPhi as we seek to develop our
bacteriophage therapeutics for patients suffering from life-threatening
bacterial infections," said Paul C. Grint, M.D., CEO of AmpliPhi
Biosciences. "We believe our GMP manufacturing facility now has the
capacity to produce AB-SA01 needed for our planned clinical trials, and
through the potential filing of a biologics license application and
regulatory approval."

Each drug substance batch produced at AmpliPhi's wholly owned GMP
facility can now provide material for over 100,000 doses, an increase in
yield of approximately 10-fold compared to its previous manufacturing
process capability.

During 2017-2018, over 1,000 doses of bacteriophage therapeutics from
AmpliPhi's facility were provided to patients with life-threatening
infections not responding to antibiotics, under emergency treatment
protocols as part of the company's expanded access program.

In September 2018, AmpliPhi announced that the U.S. Food and Drug
Administration (FDA) was in general agreement with the company's trial
designs for Phase 1/2 clinical trials for AB-SA01 in patients with S.
aureus
bacteremia and, separately, in patients with a hip or knee
prosthetic joint infection due to S. aureus as an adjunct to
surgical treatment. AmpliPhi intends to initiate the S. aureus bacteremia
clinical trial in 2019.

About AB-SA01

AB-SA01 is a clinical stage targeted bacteriophage therapeutic candidate
in clinical development for the treatment of serious and
life-threatening S. aureus infections, including those that do
not respond to any antibiotics. In preclinical studies, AB-SA01
demonstrated broad activity against 95% of global S. aureus
multidrug-resistant clinical isolates. AB-SA01 is manufactured in a
GMP-certified facility dedicated to the production of bacteriophage
products for human use.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a clinical-stage biotechnology
company focused on discovering and developing targeted therapeutics for
patients with serious and life-threatening infectious diseases,
including bacterial infections that are resistant to all antibiotics.
AmpliPhi's lead investigational product candidates are bacteriophage
therapeutics that target Staphylococcus aureus and Pseudomonas
aeruginosa, which are included as High and Critical on the WHO Priority
Pathogens List. Bacteriophage therapeutics are uniquely positioned to
address the threat of antibiotic resistance as they can be precisely
targeted to kill pathogenic bacteria, have a differentiated mechanism of
action, can penetrate and disrupt biofilm, and have been shown to
restore antibiotic sensitivity to drug-resistant bacteria.

Forward Looking Statements

Statements in this press release that are not statements of historical
fact are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include, without limitation, statements regarding: AmpliPhi's
intention to initiate a clinical trial of AB-SA01 for S. aureus bacteremia
in 2019; the capacity of AmpliPhi's manufacturing facility to produce
sufficient quantities of AB-SA01 for its planned clinical trials, and
through the potential filing of a biologics license application and
regulatory approval; the potential benefits of phage therapy; and the
potential use of bacteriophages to treat bacterial infections, including
infections that do not respond to antibiotics or are associated with
biofilms. Words such as "believe," "anticipate," "plan," "expect,"
"intend," "will," "may," "goal," "potential" and similar expressions are
intended to identify forward-looking statements, though not all
forward-looking statements necessarily contain these identifying words.
Among the factors that could cause actual results to differ materially
from those indicated in these forward-looking statements are risks and
uncertainties associated with manufacturing bacteriophage product
candidates; bacteriophage product candidate development, generally,
through expanded access regulations, and in the clinic; AmpliPhi's
financial condition; and other risks and uncertainties described in
AmpliPhi's Annual Report on Form 10-K for the year ended December 31,
2017, as filed with the Securities and Exchange Commission (SEC), and
AmpliPhi's subsequent filings with the SEC. You are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. All forward-looking
statements are qualified in their entirety by this cautionary statement,
and AmpliPhi undertakes no obligation to revise or update any
forward-looking statements to reflect events or circumstances after the
date of this press release.

View Comments and Join the Discussion!